http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0313289-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8659631bf38b3a590c0d3edc265492c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-16 |
| filingDate | 1988-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8791cbdbf9129ad5c7f71a630b8299b8 |
| publicationDate | 1989-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0313289-A2 |
| titleOfInvention | Process for the preparation of purine compounds and intermediates therefor |
| abstract | A process for the preparation of compounds of formula (I), and pharmaceutically acceptable salts thereof:n wherein nR₁ is hydrogen or CH₂OH; nR₂ is hydrogen or, (when R₁ is hydrogen), hydroxy or CH₂OH; nR₃ is CH₂OH or, (when R₁ and R₂ are both hydrogen), CH(OH)CH₂OH; nR₄ is hydrogen, hydroxy, amino or OR₅ nwherein nR₅ is C₁₋₆ alkyl, phenyl or phenyl C₁₋₂ alkyl either of which phenyl moieties may be substituted by one or two halo, C₁₋₄ alkyl or C₁₋₄ alkoxy groups; nand in which any OH groups in R₁, R₂ and/or R₃ may be in the form of O-acyl, phosphate, cyclic acetal or cyclic carbonate derivatives thereof; nwhich process comprises the reaction of a compound of formula (II): n wherein R₄′ is R₄ or a group or atom convertible thereto and R x is amino or protected amino; with a compound of formula (III): n nR₃′CHR₂′CHR₁′Q (III) n nwherein Q is a leaving group and R₁′, R₂′ and R₃′ are R₁, R₂ and R₃ respectively or R₁, R₂ and/or R₃ wherein the OH group(s) is/are in protected form; and thereafter converting R₄′ when other than R₄, to an R₄ moiety or converting R₄′, when R₄ to other R₄; if necessary converting R₁', R₂' or R₃' to R₁, R₁ and R₃ respectively and optionally forming a pharmaceutically acceptable salt, O-acyl, phosphate, cyclic acetal or cyclic carbonate derivative thereof. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9521161-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0405748-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5247085-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5108994-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6448403-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0413544-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9422864-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0404296-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5166198-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5252575-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0413544-A2 |
| priorityDate | 1987-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 340.